NCT06444087 - Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation | Biotech Hunter

Enrollment

177

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

March 30, 2027

Study Completion Date

March 30, 2027

Conditions

Hidradenitis Suppurativa

Interventions

OTHER

secukinumab

This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Trial Locations (20)

12000

RECRUITING

Novartis Investigative Site, Rodez

17019

RECRUITING

Novartis Investigative Site, La Rochelle

21034

RECRUITING

Novartis Investigative Site, Dijon

29609

RECRUITING

Novartis Investigative Site, Brest

31400

RECRUITING

Novartis Investigative Site, Toulouse

33075

RECRUITING

Novartis Investigative Site, Bordeaux

34295

RECRUITING

Novartis Investigative Site, Montpellier

44093

RECRUITING

Novartis Investigative Site, Nantes

56000

RECRUITING

Novartis Investigative Site, Vannes

56322

RECRUITING

Novartis Investigative Site, Lorient

59037

RECRUITING

Novartis Investigative Site, Lille

62100

RECRUITING

Novartis Investigative Site, Calais

69003

RECRUITING

Novartis Investigative Site, Lyon

72000

RECRUITING

Novartis Investigative Site, Le Mans

75014

RECRUITING

Novartis Investigative Site, Paris

76031

RECRUITING

Novartis Investigative Site, Rouen

92160

RECRUITING

Novartis Investigative Site, Antony

94160

RECRUITING

Novartis Investigative Site, Saint-Mandé

97410

RECRUITING

Novartis Investigative Site, Saint-Pierre

06000

RECRUITING

Novartis Investigative Site, Nice